Objective We have developed a new conceptual model to characterise the signs and symptoms of SLE: the Type 1 and 2 SLE Model. Within the original model, Type 1 SLE consists of inflammatory ...

4 Department of Preventive Medicine, Feinberg School of Medicine, Chicago, Illinois, USA Background/objective Patients with systemic lupus erythematosus (SLE) are at increased risk for adverse ...

Objective To assess the efficacy of anifrolumab, a type-1 interferon receptor subunit-1 monoclonal antibody, in treating refractory cutaneous lupus erythematosus (CLE) and lupus non-specific ...

Objective To determine frequency, demographic and treatment characteristics of patients with an overlapping second autoimmune illness (2nd AI). Methods We analysed two cohorts containing 897 patients ...

Background and aims Systemic lupus erythematosus (SLE) predominantly affects individuals at peak age of productivity, and medical costs negatively impact on personal, family and community resources.

Hospitalised infections and rituximab administration among children and adolescents with systemic lupus erythematosus from 2009 to 2021 (12 September, 2024) ...

Objectives Chorea, characterised by involuntary, irregular movements, is a rare neurological manifestation of antiphospholipid syndrome (APS). The specific clinical features remain unclear. This study ...

Objectives In SLE, deregulation of haematopoiesis is characterised by inflammatory priming and myeloid skewing of haematopoietic stem and progenitor cells (HSPCs). We sought to investigate the role of ...

Case 1: A 40-year-old male with antiphospholipid syndrome A 40-year-old Caucasian male with history of antiphospholipid syndrome (APS) was admitted to the Hospital Clinic Barcelona with hemoptysis, ...

Systemic lupus erythematosus (SLE) predominantly affects young individuals with potential to be productive members of society. SLE also significantly increases healthcare utilization with higher ...

Immune dysregulation in systemic lupus erythematosus (SLE) results in the autoimmune manifestations of SLE, but also leads to an impaired immune response to pathogens and vulnerability to infections ...

With its first description published in 1976 the bimodal mortality pattern in systemic lupus erythematosus (SLE) described early mortality as usually being due to lupus disease itself or infection, ...